Opinion: How a controversial rule could hurt the NIH’s ability to manage risk
The proposed rule could “weaken the NIH’s benign influence over research risks,” writes Doni Bloomfield.
Useful signal?
Sign in with GitHub below to react 👍 / 👎, or comment if a category looks wrong — your reactions help curate this feed. How feedback works